Complete clinical regression of a BRAF V600E-mutant pediatric glioblastoma multiforme after BRAF inhibitor therapy
- Location
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
1471-2407
- Extent
-
Online-Ressource
- Language
-
Englisch
- Notes
-
online resource.
- Bibliographic citation
-
Complete clinical regression of a BRAF V600E-mutant pediatric glioblastoma multiforme after BRAF inhibitor therapy ; volume:14 ; number:1 ; day:12 ; month:4 ; year:2014 ; pages:1-5 ; date:12.2014
BMC cancer ; 14, Heft 1 (12.4.2014), 1-5, 12.2014
- Creator
- Contributor
-
Orr, Brent A.
Gajjar, Amar
SpringerLink (Online service)
- DOI
-
10.1186/1471-2407-14-258
- URN
-
urn:nbn:de:1111-2016030421456
- Rights
-
Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Last update
-
15.08.2025, 7:23 AM CEST
Data provider
This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Associated
- Robinson, Giles W.
- Orr, Brent A.
- Gajjar, Amar
- SpringerLink (Online service)
Other Objects (12)
BRAF V600E-Mutant Glioblastoma with Extracranial Metastases Responsive to Combined BRAF and MEK Targeted Inhibition: A Case Report
Differential responsiveness to BRAF inhibitors of melanoma cell lines BRAF V600E-mutated
Early molecular diagnosis of BRAF status drives the neurosurgical management in BRAF V600E-mutant pediatric low-grade gliomas: a case report
Dramatic response of BRAF V600E-mutant epithelioid glioblastoma to combination therapy with BRAF and MEK inhibitor: establishment and xenograft of a cell line to predict clinical efficacy
Selective inhibition of V600E-mutant BRAF gene induces apoptosis in thyroid carcinoma cell lines
BRAF inhibitors in BRAF V600E-mutated ameloblastoma: systematic review of rare cases in the literature
BCL-XL inhibitors enhance the apoptotic efficacy of BRAF inhibitors in BRAF V600E colorectal cancer
Validierung eines Protokolls zur manuellen, mutationsspezifischen BRAF V600E Immunhistochemie
RNF43 mutations predict response to anti-BRAF/EGFR combinatory therapies in BRAF V600E metastatic colorectal cancer
Silencing FOXP2 reverses vemurafenib resistance in BRAF V600E mutant papillary thyroid cancer and melanoma cells
Concurrent involvement of the bone marrow by BRAF V600E–mutant melanoma and hairy cell leukemia
BRAF and MEK Inhibitor Treatment for Metastatic Undifferentiated Sarcoma of the Spermatic Cord with BRAF V600E Mutation
BRAF V600E-Mutant Glioblastoma with Extracranial Metastases Responsive to Combined BRAF and MEK Targeted Inhibition: A Case Report
Differential responsiveness to BRAF inhibitors of melanoma cell lines BRAF V600E-mutated
Early molecular diagnosis of BRAF status drives the neurosurgical management in BRAF V600E-mutant pediatric low-grade gliomas: a case report
Dramatic response of BRAF V600E-mutant epithelioid glioblastoma to combination therapy with BRAF and MEK inhibitor: establishment and xenograft of a cell line to predict clinical efficacy
Selective inhibition of V600E-mutant BRAF gene induces apoptosis in thyroid carcinoma cell lines
BRAF inhibitors in BRAF V600E-mutated ameloblastoma: systematic review of rare cases in the literature
BCL-XL inhibitors enhance the apoptotic efficacy of BRAF inhibitors in BRAF V600E colorectal cancer
Validierung eines Protokolls zur manuellen, mutationsspezifischen BRAF V600E Immunhistochemie
RNF43 mutations predict response to anti-BRAF/EGFR combinatory therapies in BRAF V600E metastatic colorectal cancer
Silencing FOXP2 reverses vemurafenib resistance in BRAF V600E mutant papillary thyroid cancer and melanoma cells
Concurrent involvement of the bone marrow by BRAF V600E–mutant melanoma and hairy cell leukemia
BRAF and MEK Inhibitor Treatment for Metastatic Undifferentiated Sarcoma of the Spermatic Cord with BRAF V600E Mutation
BRAF V600E-Mutant Glioblastoma with Extracranial Metastases Responsive to Combined BRAF and MEK Targeted Inhibition: A Case Report
Differential responsiveness to BRAF inhibitors of melanoma cell lines BRAF V600E-mutated
Early molecular diagnosis of BRAF status drives the neurosurgical management in BRAF V600E-mutant pediatric low-grade gliomas: a case report
Dramatic response of BRAF V600E-mutant epithelioid glioblastoma to combination therapy with BRAF and MEK inhibitor: establishment and xenograft of a cell line to predict clinical efficacy
Selective inhibition of V600E-mutant BRAF gene induces apoptosis in thyroid carcinoma cell lines
BRAF inhibitors in BRAF V600E-mutated ameloblastoma: systematic review of rare cases in the literature
BCL-XL inhibitors enhance the apoptotic efficacy of BRAF inhibitors in BRAF V600E colorectal cancer
Validierung eines Protokolls zur manuellen, mutationsspezifischen BRAF V600E Immunhistochemie
RNF43 mutations predict response to anti-BRAF/EGFR combinatory therapies in BRAF V600E metastatic colorectal cancer
Silencing FOXP2 reverses vemurafenib resistance in BRAF V600E mutant papillary thyroid cancer and melanoma cells
Concurrent involvement of the bone marrow by BRAF V600E–mutant melanoma and hairy cell leukemia